Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Esbriet
Esbriet
With patent concerns looming, Roche gets a new priority review on blockbuster IPF drug
With patent concerns looming, Roche gets a new priority review on blockbuster IPF drug
Endpoints
Roche
Esbriet
IPF
FDA
priority review
Flag link:
Genentech's Esbriet Granted Breakthrough Therapy Designation for uILD
Genentech's Esbriet Granted Breakthrough Therapy Designation for uILD
BioSpace
Genentech
Esbriet
uILD
breakthrough therapy
FDA
Flag link:
Genentech Plans Legal Battle to Protect Esbriet from Generic Competition
Genentech Plans Legal Battle to Protect Esbriet from Generic Competition
BioSpace
Genentech
Roche
idiopathic pulmonary fibrosis
Esbriet
generics
Flag link:
Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF
Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF
Fierce Pharma Marketing
Boehringer Ingelheim
drug reps
Ofev
Roche
Esbriet
IPF
Flag link:
Roche, Boehringer Drugs Wins Approval for Lung Disease
Roche, Boehringer Drugs Wins Approval for Lung Disease
Bloomberg
Roche
Boehringer Ingelheim
FDA
IPF
idiopathic pulmonary fibros
Esbriet
Ofev
Flag link:
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
Yahoo/Benzinga
FDA
drug approvals
Acadia
Alexion
InterMune
Merrimack Pharmaceuticals
Soliris
pimavanserin
MM-398
Esbriet
Flag link:
The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
24/7 Wall St
Alexion
InterMune
FDA
Acadia
Kythera
Intercept Pharmaceuticals
Merrimack Pharmaceuticals
Relypsa
MM-398
patiromer
Esbriet
ATX-101
Soliris
Flint
pimavanserin
Flag link:
InterMune's A Strong Buy As Esbriet Finally Has The Data Physicians, Patients, And FDA Have Longed For
InterMune's A Strong Buy As Esbriet Finally Has The Data Physicians, Patients, And FDA Have Longed For
Seeking Alpha
InterMune
Esbriet
Actelion
Gilead Sciences
Flag link:
Better Buyout Candidate: Chelsea Therapeutics International Ltd. vs. InterMune Inc.
Better Buyout Candidate: Chelsea Therapeutics International Ltd. vs. InterMune Inc.
Motley Fool
Chelsea Therapeutics
Northera
Esbriet
idiopathic pulmonary fibrosis
InterMune
Flag link:
InterMune Rises on Takeover Rumour
InterMune Rises on Takeover Rumour
Yahoo/Zacks.com
M&A
InterMune
Sanofi
Esbriet
Boehringer Ingelheim
Novartis
Flag link:
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data
Yahoo/Zacks.com
InterMune
Esbriet
Alexion
Soliris
Vivus
Qsymia
Regeneron
Eylea
Flag link:
InterMune: Esbriet And Ascend Will Drive Growth
InterMune: Esbriet And Ascend Will Drive Growth
Seeking Alpha
InterMune
Esbriet
idiopathic pulmonary fibrosis
Flag link:
InterMune says it is selling 6.5M shares to fund marketing and studies of lung disease drug
InterMune says it is selling 6.5M shares to fund marketing and studies of lung disease drug
Yahoo/AP
InterMune
stock offering
Esbriet
Flag link:
InterMune Successfully Entering Huge Niche Market Unchallenged
InterMune Successfully Entering Huge Niche Market Unchallenged
Seeking Alpha
InterMune
Esbriet
idiopathic pulmonary fibrosis
Flag link:
SEC Sues Ex-InterMune Finance Chief Alleging Esbriet Tips
SEC Sues Ex-InterMune Finance Chief Alleging Esbriet Tips
Bloomberg
SEC
InterMune
Esbriet
Flag link:
InterMune Sale Looms as Lung Drug Nears FDA Nod: Real M&A
InterMune Sale Looms as Lung Drug Nears FDA Nod: Real M&A
Bloomberg
FDA
InterMune
M&A
Esbriet
Flag link:
Rejection of InterMune’s Drug Told Early to FDA Advisers
Rejection of InterMune’s Drug Told Early to FDA Advisers
Bloomberg
FDA
InterMune
Esbriet
IPF
Flag link:
Esbriet Sales Demonstrating Growth; Expansion into New Markets Continues
Esbriet Sales Demonstrating Growth; Expansion into New Markets Continues
Yahoo/Reuters
Esbriet
InterMune
Flag link:
Why InterMune Shares Plunged
Why InterMune Shares Plunged
Motley Fool
InterMune
Esbriet
Flag link:
Drug Pricing Takes This Biotech on a Rollercoaster
Drug Pricing Takes This Biotech on a Rollercoaster
Motley Fool
InterMune
idiopathic pulmonary fibrosis
Esbriet
Flag link:
Pages
1
2
next ›
last »